MCID: TRN048
MIFTS: 12

Transitional Cell Carcinoma of the Corpus Uteri

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Transitional Cell Carcinoma of the Corpus Uteri

MalaCards integrated aliases for Transitional Cell Carcinoma of the Corpus Uteri:

Name: Transitional Cell Carcinoma of the Corpus Uteri 60
Endometrial Transitional Cell Carcinoma 60 74

Classifications:



External Ids:

ICD10 via Orphanet 35 C54.1
Orphanet 60 ORPHA213746
UMLS 74 C1516864

Summaries for Transitional Cell Carcinoma of the Corpus Uteri

MalaCards based summary : Transitional Cell Carcinoma of the Corpus Uteri, also known as endometrial transitional cell carcinoma, is related to endometrial transitional cell carcinoma. The drugs Nintedanib and Ipilimumab have been mentioned in the context of this disorder. Affiliated tissues include endothelial.

Related Diseases for Transitional Cell Carcinoma of the Corpus Uteri

Diseases related to Transitional Cell Carcinoma of the Corpus Uteri via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 endometrial transitional cell carcinoma 12.5

Symptoms & Phenotypes for Transitional Cell Carcinoma of the Corpus Uteri

Drugs & Therapeutics for Transitional Cell Carcinoma of the Corpus Uteri

Drugs for Transitional Cell Carcinoma of the Corpus Uteri (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nintedanib Approved Phase 2 656247-17-5 56843413
2
Ipilimumab Approved Phase 2 477202-00-9
3
nivolumab Approved Phase 2 946414-94-4
4
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
5 Immunologic Factors Phase 2,Phase 1
6 Immunoglobulins Phase 2,Phase 1
7 Immunoglobulin Fc Fragments Phase 2
8 Antibodies Phase 2,Phase 1
9 Mitogens Phase 2,Phase 1
10 Antineoplastic Agents, Immunological Phase 2,Phase 1
11 Antibodies, Monoclonal Phase 2,Phase 1
12
Dasatinib Approved, Investigational Phase 1 302962-49-8 3062316
13
Carboplatin Approved Phase 1 41575-94-4 10339178 38904 498142
14
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
15
Bevacizumab Approved, Investigational Phase 1 216974-75-3
16 Protein Kinase Inhibitors Phase 1
17 Antineoplastic Agents, Phytogenic Phase 1
18 Antimitotic Agents Phase 1
19 Albumin-Bound Paclitaxel Phase 1
20 Angiogenesis Modulating Agents Phase 1
21 Immunoglobulin G Phase 1
22 Endothelial Growth Factors Phase 1
23 Angiogenesis Inhibitors Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
2 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
3 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
4 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
5 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
6 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation

Search NIH Clinical Center for Transitional Cell Carcinoma of the Corpus Uteri

Genetic Tests for Transitional Cell Carcinoma of the Corpus Uteri

Anatomical Context for Transitional Cell Carcinoma of the Corpus Uteri

MalaCards organs/tissues related to Transitional Cell Carcinoma of the Corpus Uteri:

42
Endothelial

Publications for Transitional Cell Carcinoma of the Corpus Uteri

Variations for Transitional Cell Carcinoma of the Corpus Uteri

Expression for Transitional Cell Carcinoma of the Corpus Uteri

Search GEO for disease gene expression data for Transitional Cell Carcinoma of the Corpus Uteri.

Pathways for Transitional Cell Carcinoma of the Corpus Uteri

GO Terms for Transitional Cell Carcinoma of the Corpus Uteri

Sources for Transitional Cell Carcinoma of the Corpus Uteri

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....